June 08, 2016
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Media
June 07, 2016
Targovax ASA: Patient recruitment for TG01 immuno-oncology trial completed
June 06, 2016
Aprea AB announces efficacy and safety data in high-grade serous ovarian cancer patients treated with investigational APR-246 presented at 2016 ASCO Annual Meeting
June 02, 2016
Strongbridge Biopharma plc Announces Presentation at Jefferies 2016 Healthcare Conference
June 02, 2016
Publication of the LOCATION clinical study results in the renowned scientific journal of the European Atherosclerosis Society (EAS)
June 02, 2016
Targovax receives approval in Australia to conduct a clinical trial withTG02 – an immunotheraphy treatment targeting RAS mutations
June 01, 2016
BONESUPPORT™ Announces Nature Publication Of Pre-Clinical Study Highlighting CERAMENT™’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease
May 31, 2016
Strongbridge Biopharma plc Announces Presentation of COR-003 and COR-005 Data at the European Congress of Endocrinology
May 31, 2016
NORDIC NANOVECTOR CAPITAL MARKETS DAY 2016 TO HIGHLIGHT STRONG PROGRESS TOWARDS VISION OF BECOMING A SIGNIFICANT PLAYER IN HAEMATOLOGICAL CANCERS
May 31, 2016
Targovax to present at forthcoming conferences
